US Pharma MarketingThe post ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection appeared first on Medical Device Network.
ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ASCO 2026. Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ASCO 2026. One of the most common cancers globally, around 2.3 million women were diagnosed with breast cancer in 2022, as per the World Health Organization. Credit: Katsiaryna Hurava / Shutterstock.com Veracyte’s genomic assay and GRAIL’s multi-cancer early detection (MCED) have demonstrated respective benefits in informing breast cancer treatment decision making and in detecting cancer earlier when used alongside standard of care…
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ASCO 2026.
Source: Medical Device Network